Big cash raise and strong Phase 3 results headline Xenon (XENE) Q1 2026
Rhea-AI Filing Summary
Xenon Pharmaceuticals reported a larger net loss in Q1 2026 as it ramps late‑stage neuroscience programs but highlighted pivotal clinical progress and a strengthened balance sheet. The company posted a net loss of $102.3 million (vs. $65.0 million a year ago), driven by higher research and development and general and administrative expenses and the absence of prior collaboration revenue.
Cash, cash equivalents, and marketable securities rose to $1.34 billion as of March 31, 2026, after raising $130.0 million via an at‑the‑market program and $707.6 million through a public offering, extending cash runway into 2029. Xenon reported positive Phase 3 X‑TOLE2 data for azetukalner in focal onset seizures, with a placebo‑adjusted median percent change in monthly seizure frequency of -42.7% at 25 mg, and plans a New Drug Application submission in Q3 2026. Multiple additional Phase 3 studies in epilepsy and mood disorders, as well as Phase 1 pain programs targeting NaV1.7 and KV7, continue to enroll or progress.
Positive
- Transformative Phase 3 efficacy in focal onset seizures: X‑TOLE2 achieved a placebo‑adjusted median percent change in monthly FOS frequency of -42.7% at 25 mg, supporting an NDA submission for azetukalner in Q3 2026.
- Substantially strengthened balance sheet and runway: Cash, cash equivalents, and marketable securities increased to $1.34 billion as of March 31, 2026, after raising $837.6 million in net equity proceeds, extending cash runway into 2029.
Negative
- Materially higher quarterly net loss: Net loss widened to $102.3 million in Q1 2026 from $65.0 million a year earlier, reflecting higher R&D and G&A expenses and the absence of prior collaboration revenue.
- Growing operating expense base: Research and development expenses rose to $88.5 million and general and administrative expenses to $23.8 million in Q1 2026, increasing the company’s cash burn as late‑stage programs expand.
Insights
Strong Phase 3 data and a major cash build offset widening losses.
Xenon Pharmaceuticals delivered compelling Phase 3 X‑TOLE2 results in focal onset seizures, with a placebo‑adjusted median percent change in seizure frequency of -42.7% at 25 mg. This supports the planned azetukalner NDA submission to the FDA in Q3 2026 and underpins a broad late‑stage program across epilepsy and mood disorders.
Financially, Xenon reported a $102.3 million net loss in Q1 2026 versus $65.0 million a year earlier, reflecting higher R&D and G&A spending and the loss of prior collaboration revenue. However, cash, cash equivalents, and marketable securities increased to $1.34 billion, bolstered by $130.0 million raised under its ATM and $707.6 million from a public offering, extending runway into 2029.
The key dependencies are successful NDA review, outcomes of ongoing Phase 3 trials in epilepsy, major depressive disorder, and bipolar depression, and Phase 1 completions for NaV1.7 and KV7 pain programs expected in H2 2026. Subsequent disclosures on regulatory interactions and additional Phase 3 readouts, including X‑NOVA2 topline data expected in H1 2027, will clarify how this investment in development translates into potential future revenue.
8-K Event Classification
Key Figures
Key Terms
focal onset seizures (FOS) medical
New Drug Application (NDA) regulatory
median percent change (MPC) financial
open-label extension (OLE) medical
major depressive disorder (MDD) medical
bipolar depression (BPD) medical
Earnings Snapshot
Based on current operating plans, Xenon anticipates having sufficient cash to fund operations into 2029.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading |
|
Name of each exchange on which registered |
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 |
Results of Operations and Financial Condition |
On May 7, 2026, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release the Company’s financial results for the three months ended March 31, 2026. A copy of the Company’s press release is attached hereto as Exhibit 99.1. The information in Item 2.02 of this Form 8-K and the attached exhibit are furnished to, but not filed with, the Securities and Exchange Commission.
Item 7.01 |
Regulation FD Disclosure |
The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company’s website (https://www.xenon-pharma.com), its investor relations website (https://investor.xenon-pharma.com), and its news site (https://investor.xenon-pharma.com/news-releases). The Company uses these channels, as well as social media, including its X (formerly known as Twitter) account (@XenonPharma), LinkedIn account (https://www.linkedin.com/company/xenonpharma/), and Facebook page (https://www.facebook.com/xenonpharma), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.
Item 9.01 |
Financial Statements and Exhibits |
(d) Exhibits.
Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission:
Exhibit Number |
Description |
99.1 |
Press Release issued by Xenon Pharmaceuticals Inc. dated May 7, 2026. |
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
XENON PHARMACEUTICALS INC. |
|
|
|
|
|
Date: May 7, 2026 |
|
By: |
/s/ Thomas P. Kelly |
|
|
|
Thomas P. Kelly |
|
|
|
Chief Financial Officer |
Exhibit 99.1
Xenon Reports Q1 2026 Financial Results and Provides Business Update
VANCOUVER, British Columbia and BOSTON, MA, May 7, 2026 (GLOBE NEWSWIRE) – Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today reported financial results for the first quarter ended March 31, 2026 and provided a business update.
“In the first quarter of 2026, we announced positive results from our X-TOLE2 study, which exceeded expectations and reinforced azetukalner’s significant potential to provide a new therapeutic option for FOS patients with uncontrolled seizures. The strong X-TOLE2 results have paved the way for us to submit an NDA to the FDA in the third quarter of 2026 and our commercial preparedness activities are well underway, supported by our strong balance sheet with cash runway into 2029,” said Ian Mortimer, President and Chief Executive Officer of Xenon. “We remain enthusiastic about broadening the opportunity for azetukalner beyond FOS and are making good progress advancing multiple additional Phase 3 studies in epilepsy and neuropsychiatry indications. Additionally, we are looking forward to completing the first-in-human data for our novel programs targeting NaV1.7 and KV7 in pain later this year.”
Business Highlights and Anticipated Milestones
Azetukalner Clinical Development
Azetukalner is a novel, potent KV7 potassium channel opener in Phase 3 clinical development for multiple indications, including two in epilepsy – focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS) – as well as neuropsychiatric disorders, including major depressive disorder (MDD) and bipolar depression (BPD).
Epilepsy Programs
Depression Programs
Early-Stage R&D
Xenon continues to expand its portfolio of potent, selective ion channel modulators using the Company’s strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries. This includes clinical-stage candidates targeting NaV1.7 and KV7, which are important targets for pain.
NaV1.7 and KV7 in Pain
NaV1.1 in Epilepsy
Partnered Program
Upcoming Investor Conferences
Q1 2026 Financial Results
Conference Call Information
Xenon will host a conference call and webcast today at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss its first quarter 2026 results. A listen-only webcast can be accessed on the Investors section of the Xenon website, with a replay available following the event. Participants can access the conference call by dialing (800) 715-9871 or (646) 307-1963 for international callers and referencing conference ID 7898598.
About Azetukalner
Azetukalner is a novel, potent KV7 potassium channel opener currently in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). It represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development. Azetukalner is designed to open potassium channels in the central nervous system, allowing potassium ions to flow and hyperpolarizing neurons. This process helps reduce excessive neuronal firing, which is a key contributor to several neurologic and psychiatric disorders. It is the only KV7 potassium channel opener in development for multiple indications that is backed by long-term efficacy and safety data in epilepsy patients and proof-of-concept data in MDD patients.
Phase 3 Epilepsy Studies
Xenon’s clinical development program for azetukalner in epilepsy includes three Phase 3 clinical studies in focal onset seizures (FOS) and primary generalized tonic-clonic seizures (PGTCS). The completed X-TOLE2 study and the ongoing X-TOLE3 study were both designed as multicenter, randomized, double-blind, placebo-controlled studies to evaluate the clinical efficacy, safety, and tolerability of 15 mg or 25 mg of azetukalner administered orally with food as adjunctive treatment in approximately 360 patients with FOS per study. The primary efficacy endpoint is the median percent change (MPC) in monthly seizure frequency from baseline through the 12-week double-blind period (DBP) of azetukalner compared to placebo.
X-ACKT is a multicenter, randomized, double-blind, placebo-controlled study evaluating the clinical efficacy, safety, and tolerability of 25 mg of azetukalner administered with food as adjunctive treatment in approximately 160 patients with PGTCS. The primary efficacy endpoint is the MPC in monthly PGTCS frequency from baseline through the 12-week DBP of azetukalner compared to placebo.
Upon completion of the DBP in the Phase 3 epilepsy studies, eligible patients may enter an open-label extension (OLE) study for up to six years.
Phase 3 MDD Studies
Xenon’s Phase 3 X-NOVA major depressive disorder (MDD) program includes three multicenter, randomized, double-blind, placebo-controlled clinical studies to evaluate the clinical efficacy, safety, and tolerability of 20 mg of azetukalner administered orally with food over the 6-week double-blind period (DBP) as monotherapy treatment in approximately 450 patients with moderate-to-severe major depressive disorder (MDD) per study. The primary efficacy endpoint is the change from baseline in the HAM-D17 score at week 6 in patients who received azetukalner compared to placebo. Upon completion of the DBP, eligible patients may enter an open-label extension (OLE) study for up to 12 months.
Phase 3 BPD Studies
Xenon’s Phase 3 X-CEED Bipolar Depression (BPD) program includes two multicenter, randomized, double-blind, placebo-controlled clinical studies to evaluate the clinical efficacy, safety, and tolerability of 20 mg of azetukalner administered orally with food over the 6-week double-blind period (DBP) as monotherapy treatment in approximately 400 patients per study with BPD I or II. The primary efficacy endpoint is the change from baseline in the MADRS score at week 6 in patients who received azetukalner compared to placebo. Upon completion of the DBP, eligible patients may enter an open-label extension (OLE) study for up to 12 months.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical studies; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners’ product candidates; the efficacy of our clinical study designs; our ability to successfully develop and achieve milestones in our azetukalner and other pipeline and development programs, including the potential timing of trial enrollment completion and the anticipated filing of INDs and NDAs; the timing and results of our interactions with regulators, including the timing of any NDA submission; and our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical studies may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical study results may not be replicated in later clinical studies; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators’ product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation or completion of clinical studies; the impact of market, industry, and regulatory conditions on clinical study enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.
Contacts
For Investors:
Tucker Kelly
Chief Financial Officer
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
media@xenon-pharma.com
XENON PHARMACEUTICALS INC.
Condensed Consolidated Balance Sheets
(Expressed in thousands of U.S. dollars)
|
|
March 31, |
|
|
December 31, |
|
||
|
|
2026 |
|
|
2025 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash, cash equivalents and marketable securities |
|
$ |
1,094,747 |
|
|
$ |
548,886 |
|
Other current assets |
|
|
11,885 |
|
|
|
11,763 |
|
Marketable securities, long-term |
|
|
244,874 |
|
|
|
37,152 |
|
Other long-term assets |
|
|
35,304 |
|
|
|
35,362 |
|
Total assets |
|
$ |
1,386,810 |
|
|
$ |
633,163 |
|
|
|
|
|
|
|
|
||
Liabilities |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable and accrued liabilities |
|
$ |
38,254 |
|
|
$ |
40,260 |
|
Other current liabilities |
|
|
1,561 |
|
|
|
1,532 |
|
Other long-term liabilities |
|
|
9,176 |
|
|
|
9,611 |
|
Total liabilities |
|
$ |
48,991 |
|
|
$ |
51,403 |
|
|
|
|
|
|
|
|
||
Shareholders’ equity |
|
$ |
1,337,819 |
|
|
$ |
581,760 |
|
Total liabilities and shareholders’ equity |
|
$ |
1,386,810 |
|
|
$ |
633,163 |
|
XENON PHARMACEUTICALS INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Expressed in thousands of U.S. dollars except share and per share amounts)
|
|
Three Months Ended |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Revenue |
|
$ |
— |
|
|
$ |
7,500 |
|
|
|
|
|
|
|
|
||
Operating expenses: |
|
|
|
|
|
|
||
Research and development |
|
|
88,508 |
|
|
|
61,200 |
|
General and administrative |
|
|
23,820 |
|
|
|
19,038 |
|
Total operating expenses |
|
|
112,328 |
|
|
|
80,238 |
|
Loss from operations |
|
|
(112,328 |
) |
|
|
(72,738 |
) |
Other income |
|
|
7,455 |
|
|
|
8,118 |
|
Loss before income taxes |
|
|
(104,873 |
) |
|
|
(64,620 |
) |
Income tax recovery (expense) |
|
|
2,571 |
|
|
|
(427 |
) |
Net loss |
|
$ |
(102,302 |
) |
|
$ |
(65,047 |
) |
|
|
|
|
|
|
|
||
Other comprehensive income (loss): |
|
|
|
|
|
|
||
Unrealized gain (loss) on available-for-sale securities |
|
|
(1,546 |
) |
|
|
776 |
|
Comprehensive loss |
|
$ |
(103,848 |
) |
|
$ |
(64,271 |
) |
|
|
|
|
|
|
|
||
Net loss per common share: |
|
|
|
|
|
|
||
Basic and diluted |
|
$ |
(1.17 |
) |
|
$ |
(0.83 |
) |
Weighted average common shares outstanding: |
|
|
|
|
|
|
||
Basic and diluted |
|
|
87,345,717 |
|
|
|
78,687,503 |
|